Meilleure Health Intrntnl Indu : VOLUNTARY ANNOUNCEMENT ACQUISITION OF CERTAIN EQUITY INTEREST IN A PRC COMPANY

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

MEILLEURE HEALTH INTERNATIONAL INDUSTRY GROUP LIMITED

美 瑞 健 康 國 際 產 業 集 團 有 限 公 司

(Incorporated in Bermuda with limited liability)

(Stock Code: 2327)

VOLUNTARY ANNOUNCEMENT ACQUISITION OF CERTAIN EQUITY INTEREST IN A PRC COMPANY

This is a voluntary announcement made by Meilleure Health International Industry Group Limited ( the

"Company" or "Meilleure Health International", together with its subsidiaries, the "Group") to inform

its shareholders of the latest business development of the Group.

Reference is made to the Company's voluntary announcement dated 12 August 2019 (the "Announcement"). Following the Announcement, on 4 September 2019 (after trading hours), the Company, through a wholly owned subsidiary, entered into an equity transfer agreement to acquire a 8.3077% equity interest (the "Equity Interest") in Shenzhen Gippro Innovation Limited ( 深圳龍舞科技創新有限公司 ) ("Gippro Shenzhen") (which Equity Interest will be diluted to 7.809231% upon completion of the subscription of the 6% equity interest in Gippro Shenzhen by the Company in accordance with the Capital Increase Agreement referred to in the Announcement) from a natural person at the consideration of approximately RMB10,802,969. The consideration is calculated based on a post-investment valuation of Gippro Shenzhen in its last round of financing prior to the Company's agreeing to subscribe for a 6% equity interest in it, which is RMB130 million. Upon completion of the acquisition, the Equity Interest, coupled with the 6% equity to be subscribed for by the Company pursuant to the Capital Increase Agreement as referred to in the Announcement, will result in the Group holding an aggregate of approximately 13.809231% equity interest in Gippro Shenzhen. In addition, the Group has the right to subscribe for an additional equity interest of not more than 10% in Gippro Shenzhen, and if the Group exercises such subscription right in full, the Group will hold an aggregate of approximately 22.4283% equity interest in Gippro Shenzhen, being the after-dilution equity interest held by the Group upon completion of the subscription for an additional 10% equity interest in Gippro Shenzhen by the Company (the 13.809231% equity interest will be diluted to approximately 12.4283%). The consideration payable by the Group will be financed by the internal resources of the Group.

Gippro Shenzhen is an innovative company with the objective of expanding the market for atomization products in China. The Directors of the Company take the view that atomization products are experiencing fast growth in the Chinese market and the market size of atomization products are huge. The Company's participation in the sales and promotion of atomization products in China through this investment will create new growth opportunities for the Group.

- 1 -

The Company will continue to establish its presence in the industrial hemp market and facilitate the growth of its industrial hemp business in the future. The Company will proactively promote the research and development of drugs using CBD as components and clinical applications of CBD and accelerate and increase investments in and the building of CBD consumer brands so as to push forward the establishment of its business presence in the global industrial hemp market.

By Order of the Board

Meilleure Health International Industry Group Limited

Zhou Wen Chuan

Chief Executive Officer

Hong Kong, 4 September 2019

As at the date of this announcement, the Board comprises Mr. Zhou Xuzhou, Dr. Zeng Wentao and Ms. Zhou Wen Chuan as executive Directors, Dr. Mao Zhenhua as non-executive Director and Mr. Gao Guanjiang, Professor Chau Chi Wai, Wilton and Mr. Wu Peng as independent non-executive Directors.

- 2 -